Case Report

Clinical Rheumatology

, Volume 29, Issue 5, pp 567-571

First online:

Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review

  • Emilio BesadaAffiliated withRheumatology, University Hospital North NorwayRevmatologisk Avdeling, Nevro-og Ortopediklinikken, Universitetssykehuset Nord-Norge Email author 
  • , Hans NossentAffiliated withRheumatology, University Hospital North NorwayRheumatology, Institute of Clinical Medicine, University of Tromsø

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


We report a case of longstanding multidrug resistant Schnitzler’s syndrome that finally went into clinical remission upon treatment with anakinra and review the literature concerning IL1-RA treatment for Schnitzler’s syndrome. A now 71-year-old patient presenting with recurring episodes of urticaria and fever and secondary weight loss for the past 16 years as well as arthralgia, hearing loss. The patient has anemia, leucocytosis with neutrophilia, thrombocytosis, elevated C-reactive protein and erythrocyte sedimentation rate, lymphadenopathy and a monoclonal IgM kappa band that later became oligoclonal with two IgM kappa bands and one IgM lambda band. The patient was treated with moderate effect with combination of prednisolone, azathioprine, and colchicine. In March 2009, anakinra 100 mg daily sc was added during a disease flare. Within 24 h after the first injection, both the urticaria and the fever disappeared and have not recurred. For the past 6 months, the patient has been in clinical and biochemical remission. Colchicine has been stopped while the azathioprine and prednisolone doses are being reduced. Twenty-four patients with Schnitzler’s syndrome, including three patients with a variant of Schnitzler’s syndrome and three patients with a Schnitzler-like syndrome, have been successfully treated with anakinra. Nevertheless, seven out of seven patients, that either interrupted or used anakinra every other day, had relapse of their symptoms within 24-48 h; anakinra was restarted in all patients with the same clinical efficiency. The current case history and the literature review already suggest an important role for IL-1 as a mediator in the pathophysiology of Schnitzler’s syndrome.


Anakinra Autoinflammatory Monoclonal gammopathy Schnitzler syndrome Urticaria